Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor - Kaymakcalan, Z; Sakorafas, P; Bose, S (Clin Immunol, 2009)
et al.